摘要
眼内新生血管的发生是许多眼病的病理基础和重要临床表现,而血管内皮生长因子(VEGF)是刺激不正常的血管生长以及造成血管壁滲漏的主因,因此抗VEGF靶分子治疗成为当今的研究热点。本文综述了近年来视网膜新生血管生物药物治疗新进展,包括VEGF反义寡聚脱氧核苷酸、VEGF抗体、RNA干扰类药物等。这些方法均显示出令人振奋的效果,但仍需要经过长期、系统的临床试验检验其安全性、有效性。
Intraocular neovascularization is the pathologic basis and important clinical manifestation in numerous ocular disorders, and vascular endothelial growth factor （VEGF） is the major cause that stimulates abnormal vascular growth and leakage. So anti-VEGF treatment becomes a research focus in recent years. The present paper reviewed the new advances in this respect, such as antisense oligonucleotides, monoclonal antibody and RNA interference drug. All of these have shown very exciting results, but we still need a long time and systematic clinic tests to check their security and effectiveness.
出处
《国际眼科杂志》
CAS
2007年第4期1119-1123,共5页
International Eye Science
关键词
视网膜新生血管
血管内皮生长因子
RNA干扰
retinal neovascularization
vascular endothelial growth factor （VEGF）, RNA interference
